📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Référence presse grand public
Cité 3 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
🎓 DES & spécialité ordinale
📚 CES (Certificat d'Études Spéciales)
🎯 Capacités
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
🎓 Diplômes
📝 Autres formations
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
1
1 articles ont été cités au moins 1fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
4
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
6
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
0
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Le Berry Républicain · 07/09/2020
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQSVQwYzc2LWtlX1gxX0FUeFNaRVQxLXA1SEs1Mlhna2NQODdmenVaeGx0OU5WOTNoNEhKMndvTDZkcGp5aUY3aVFsRWN6ZHJJR3FzU2QxS1VYc3VBendqZm5yb2tXTGF3RXI1TnplRWxHSDgtUzJfNGxfVmtZUm9lSnl6R3VJRnRwa3NDYjFfNzVqQVVPcnIyeVhKLXBQZ1VLY25pZmJXUG9kank5bktLakpMNGJBRHVEeE
📰 lanouvellerepublique.fr · 01/12/2016
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQRVhIU2tkcWp2ck1zVHB1Z010X3l1RmdUTTZNV3JMYkd3eU9PRVBfWHZ5bTNMcmVwUzE2a21ja1h3N2FubUJXNllxUUloTjhfTXB0WmlrTE5Ed1lNc3dqVzBpT2NZVFFtS2tjSkVteWV6UnRXQlc5TnljaGNXVjJ2Y0UwcW1hV1R2SG1fNmQ2QWdFM18zR3BXeg?oc=5" target="_blank">Ehpad : nouvelle orga
📰 lanouvellerepublique.fr · 11/07/2016
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPbm43RFZMTHdHdV9xOWx1cHk3T3ZpX3JLVFBvLWVLSWFUZHpoa1czNjc2dHItWWxOVmRiTjIyMkpjRzU5VHE1ckJndDRCWFpTanE3dWgtWG9lckhZV2dhdXdvYUQ5cFd2SFdiZ2RWcHZKckxrSkhkMkZQUmpWNlE2S3FpVkVjaFhSOURsem5iOFhfbDlpVlh3a0Jn?oc=5" target="_blank">Des médailles, des
Cancer cytopathology · 2014
BACKGROUNDTaking into consideration the known overexpression of p16INK4a in histologically demonstrated high‐grade urothelial malignancies, the objective of the current study was to examine the value of p16INK4a overexpression and of p16/Ki‐67 dual labeling versus urinary cytology in the detection of urothelial lesions.METHODSImmunolabeling was performed on demounted and destained Papanicolaou slides after liquid‐based ThinPrep processing. Actual diagnoses were ascertained by cystoscopy controls and histopathology. Negative cases, papillary urothelial neoplasia of low malignant potential/low‐grade tumor, and high‐grade lesions were considered separately.RESULTSA total of 216 urine samples were collected from new patients with symptoms who were referred for cystoscopy (92 cases) or patients who were being followed after conservative treatment for lesions involving the bladder (117 cases) or the upper urinary tract (7 cases). p16INK4a positivity was assessed in 171 of the 216 cases (79.2%) and in 93 of 99 high‐grade cases with positive cytology (93.9%). Coexpression of p16/Ki‐67 in the same cells was observed in 119 of 216 cases (55.1%) and was noted in 18 of 51 cases of negative or papillary urothelial neoplasia of low malignant potential/low‐grade tumor (35.3%) and in 80 of 101 high‐grade tumors (79.2%) (P < .0001). Thirteen of 14 high‐grade intraurothelial lesions (92.8%) were dual labeled. When high‐grade tumors, disease progression (increased grade, muscle infiltration, and extension into the upper urinary tract), and cancer‐related death were grouped together as an endpoint, dual labeling demonstrated a sensitivity that was slightly higher than that of urinary cytology (82.5% vs 80.8%; P = .8), with 94.9% overall specificity.CONCLUSIONSWhen applied to the search for high‐grade and aggressive disease, p16/Ki‐67 dual labeling and urinary cytology appear to demonstrate comparable performance. Cancer (Cancer Cytopathol) 2014;122:211–220. © 2013 American Cancer Society.
Cancer cytopathology · 2017
BACKGROUNDOverexpression of p16INK4a has been identified in urothelial malignancies both cytologically and histologically. In addition, p16/Ki‐67 dual labeling has been shown to identify high‐grade urothelial cancer cells and some progression cases within a 12‐month delay. The Paris System for Reporting Urinary Cytology (TPS) was published in late 2015. Its aim is to clarify the criteria for diagnosing or, conversely, excluding high‐grade urothelial carcinoma (HGUC).METHODSDual labeling was performed on archived ThinPrep‐based Papanicolaou slides. A total of 208 samples (negative for high‐grade urothelial carcinoma [NHGUC], 59; consistent with low‐grade urothelial neoplasia [LGUN], 24; atypical urothelial cells [AUC], 15; and suspicious for or showing HGUC, 110) were analyzed for p16/Ki‐67 after reclassification according to TPS. We assessed the oncologic status of the patients with cystoscopy, urinary cytology, histology, and prolonged 36‐month follow‐up data.RESULTSThe sensitivity of p16/Ki‐67 for life‐threatening lesions was not different from that of urinary cytology (82.8% vs 83.6%; P = 1). However, among patients with samples classified as NHGUC and AUC, disease‐free survival was significantly shorter for dual‐labeled cases versus cases with negative dual labeling (P < .0001). The same tendency was observed in patients with histologically proven LGUN (P < .0001). As for specificity in patients with negative cystoscopy and cytology combined, prolonged follow‐up showed 90% overall survival at 24 months.CONCLUSIONSA long‐term evaluation of p16/Ki‐67 dual labeling may identify HGUC and progression in cases with negative/low‐grade urinary cytology results, and there are potential implications for the clinical management of patients after the conservative treatment of non–muscle‐invasive urothelial carcinoma. Cancer Cytopathol 2017;125:552–62. © 2017 American Cancer Society.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Cancer cytopathology · 2017 · Journal Article
Piaton E, Advenier AS, Carré C, Decaussin-Petrucci M, et al.
Cancer cytopathology · 2014 · Comparative Study
Piaton E, Carré C, Advenier AS, Decaussin-Petrucci M, et al.